Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$11.28 USD
-0.02 (-0.18%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $11.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Enanta Pharmaceuticals, Inc falls in the month of September.
All items in Millions except EPS data.
9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 | |
---|---|---|---|---|---|
Sales | 79 | 86 | 97 | 122 | 205 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 79 | 86 | 97 | 122 | 205 |
Selling & Adminstrative & Depr. & Amort Expenses | 216 | 210 | 207 | 164 | 168 |
Income After Depreciation & Amortization | -137 | -124 | -110 | -42 | 37 |
Non-Operating Income | 11 | 2 | 2 | 7 | 9 |
Interest Expense | 5 | 0 | 0 | 0 | 0 |
Pretax Income | -131 | -122 | -108 | -35 | 46 |
Income Taxes | 3 | 0 | -29 | 1 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -134 | -122 | -79 | -36 | 46 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -134 | -122 | -79 | -36 | 46 |
Depreciation Footnote | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -138 | -120 | -104 | -38 | 36 |
Depreciation & Amortization (Cash Flow) | 0 | 4 | 5 | 4 | -1 |
Income After Depreciation & Amortization | -137 | -124 | -110 | -42 | 37 |
Earnings Per Share Data | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Average Shares | 20.97 | 20.60 | 20.17 | 19.94 | 20.97 |
Diluted EPS Before Non-Recurring Items | -6.38 | -5.91 | -3.92 | -0.89 | 2.21 |
Diluted Net EPS (GAAP) | -6.38 | -5.91 | -3.92 | -1.81 | 2.21 |
Fiscal Year end for Enanta Pharmaceuticals, Inc falls in the month of September.
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 17.97 | 17.05 | 18.00 | 18.93 | 18.89 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 17.97 | 17.05 | 18.00 | 18.93 | 18.89 |
SG&A, R&D, and Dept/Amort Expenses | 42.15 | 49.83 | 52.89 | 49.97 | 55.61 |
Income After SG&A, R&D, and Dept/Amort Expenses | -24.18 | -32.78 | -34.89 | -31.04 | -36.72 |
Non-Operating Income | 3.49 | 3.81 | 4.30 | 4.66 | 3.87 |
Interest Expense | 2.36 | 2.56 | 3.44 | 3.15 | 2.00 |
Pretax Income | -23.05 | -31.52 | -34.03 | -29.52 | -34.84 |
Income Taxes | -0.40 | -0.36 | -0.62 | -1.41 | 4.22 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -22.66 | -31.16 | -33.41 | -28.11 | -39.07 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -22.66 | -31.16 | -33.41 | -28.11 | -39.07 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 21.18 | 21.17 | 21.09 | 21.06 | 21.05 |
Diluted EPS Before Non-Recurring Items | -1.07 | -1.47 | -1.58 | -1.33 | -1.86 |
Diluted Net EPS (GAAP) | -1.07 | -1.47 | -1.58 | -1.34 | -1.86 |